Pharmacodynamics In animal studies,<unk>  has been found to bind to the androgen receptor (AR) about half as strongly as DHT, and to cause side effects that are typical of 17α-alkylated AAS, such as liver damage and left ventricular hypertrophy when taken in higher doses.<unk>  is unusual in that it is structurally a 2-ene compound, lacking the 3-keto group present in almost all commercial AAS (with ethylestrenol being a rare and notable exception). This does not mean it is a weak compound, and clinical research has determined that it is a fairly potent oral agent. Rat studies indicate that<unk>  has an anabolic effect 160% that of testosterone while being only 60% as androgenic, giving it a Q ratio of 6.5:1. Because of this favorable ratio, experiments in orchiectomized rats have demonstrated that treatment with<unk>  resulted only in a stimulation of the weight of the levator ani muscle; the prostate and seminal vesicle weights remained unaffected leading the authors of one study to characterize<unk>  as a powerful AAS with attributes of a selective androgen receptor modulator (SARM) and some indication of toxicity.
Desoxymethyltestosterone
Vinyltestosterone
Ethyltestosterone
Acetothiolutamide
Cyproterone acetate
Cloxotestosterone acetate
Chloromethylandrostenediol
Cloxestradiol acetate